ClinicalTrials.gg
CompletedNCT05656885Updated Dec 27, 2023Results posted

Clinical Evaluation of Two Frequent Replacement Soft Spherical Contact Lenses

An interventional study of Lens A and Lens B in Myopia and Hyperopia, sponsored by CooperVision, Inc.. Completed at 1 site in Spain. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-12-27.

Sponsored by CooperVision, Inc. (part of CooperCompanies) · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This was a single-blind (participant masked), interventional, prospective, direct refit, bilateral wear short-term fitting study.

Read the detailed description

The aim of this non-dispensing fitting study was to evaluate the short-term clinical performance of two soft spherical contact lenses after 15 minutes of daily wear each.

02

Conditions studied

  • Myopia
  • Hyperopia

Browse trials for

03

In context

Myopia

1,007 studies on the registry are indexed under Myopia; 210 are open to participants now.

This study's enrollment of 40 is below the median of 80 across 803 interventional studies indexed under Myopia.

Browse Myopia studies →

Lead sponsor

CooperVision, Inc. is the lead sponsor of 38 studies on the registry; none are open to participants now.

Of its 32 completed or terminated interventional studies of FDA-regulated products, 30 (94%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is at least 18 years of age and has full legal capacity to volunteer.
  • Has read and signed an information consent letter.
  • Self-reports having a full eye examination in the previous two years.
  • Anticipates being able to wear the study lenses for at least 8 hours a day, 5 days a week.
  • Is willing and able to follow instructions and maintain the appointment schedule.
  • Habitual soft contact lens wearers who currently wear sphere contact lenses, or use spectacles for all distances vision correction, for the past 3 months minimum.
  • Has refractive astigmatism no higher than -0.75DC.
  • Can be fit and achieve binocular distance vision of at least 20/30 Snellen (or +0.20 logMAR) which participants also deem to be 'acceptable', with the available study lens parameters (powers +8.00 to -12.00DS)

Exclusion criteria

Exclusion Criteria:

  • Is participating in any concurrent clinical or research study.
  • Has any known active ocular disease and/or infection that contraindicates contact lens wear.
  • Has a systemic condition that in the opinion of the investigator may affect a study outcome variable.
  • Is using any systemic or topical medications that in the opinion of the investigator may affect contact lens wear or a study outcome variable.
  • Has known sensitivity to the diagnostic sodium fluorescein used in the study.
  • Self-reports as pregnant, lactating or planning a pregnancy at the time of enrolment.
  • Has undergone refractive error surgery or intraocular surgery.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Lens A

    All participants wore Lens A for 15 minutes (Period 1)

    Device: Lens A

  • Experimental
    Lens B

    All participants wore Lens B for 15 minutes (Period 2)

    Device: Lens B

Interventions

  • DeviceLens A

    Soft spherical hydrogel contact lens for 15 minutes

  • DeviceLens B

    Soft spherical silicone hydrogel contact lens for 15 minutes

06

What researchers measure

Primary outcomes

  1. Lens Fit Acceptance Rating

    Measured on lens fit alone on a scale of 0-4 (0=Should not be used; 1=Limit, but unacceptable; 2=Minimum acceptable, early review; 3=Not perfect, but OK to dispense; 4=Perfect) as assessed by an investigator.

    Time frame: 15 minutes

07

Results

Posted Dec 27, 2023

Participant flow

Period 1: Lens A, 15 Minutes
Participant flow — Period 1: Lens A, 15 Minutes
MilestoneLens A (Hydrogel Contact Lens)Lens B (Silicone Hydrogel Contact Lens)
Started400
Completed400
Not completed00
Period 2: Lens B, 15 Minutes
Participant flow — Period 2: Lens B, 15 Minutes
MilestoneLens A (Hydrogel Contact Lens)Lens B (Silicone Hydrogel Contact Lens)
Started040
Completed040
Not completed00

Outcome measures

PrimaryLens Fit Acceptance Rating

Measured on lens fit alone on a scale of 0-4 (0=Should not be used; 1=Limit, but unacceptable; 2=Minimum acceptable, early review; 3=Not perfect, but OK to dispense; 4=Perfect) as assessed by an investigator.

Time frame:
15 minutes
Reported as:
Mean · score on a scale
Lens Fit Acceptance Rating
score on a scaleLens ALens B
Lens Fit Acceptance Rating3.28 ± 0.603.48 ± 0.60

Adverse events

Collected over From dispense up to 15 minutes on each lens type, approximately 1.5 hours.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lens A0/40 (0%)0/40 (0%)0/40 (0%)
Lens B0/40 (0%)0/40 (0%)0/40 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)All Participants
Mean24.68 ± 4.57
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female31
Male9
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)All Participants
08

Study locations

1 site
  • University Complutense of Madrid
    Madrid, 28037, Spain
09

References and documents

Study documents

  • Protocol and statistical analysis plan · Jul 11, 2022

Documents are hosted by the registry — open the source record to download them.

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 27, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05656885
Lead sponsor
CooperVision, Inc.
Responsible party
Sponsor
First posted
Dec 19, 2022
Start date
Sep 27, 2022
Primary completion
Oct 18, 2022
Completion
Oct 18, 2022
Results posted
Dec 27, 2023
Last update
Dec 27, 2023

Study contacts

Juan G Carracedo Rodríguez, OD,MSc,PhD
principal investigator · University Complutense of Madrid

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion